View article

IgA nephropathy (IgAN) is the most common primary glomerulonephritis in the world. Galactose-deficient IgA1 (Gd-IgA1), anti-Gd-IgA1 autoantibodies (anti-Gd-IgA1), and IgA-IgG-containing immune complexes (ICs) are central in the pathogenesis of IgAN, contributing to kidney damage. The potential of targeting these disease-causing species was demonstrated in the Phase 2a JANUS trial (NCT02808429), evaluating the safety and efficacy of atacicept in patients with IgAN. Atacicept is a fusion protein that binds B-lymphocyte stimulator (BlyS) and a proliferation-inducing ligand (APRIL) inhibiting maturation and class-switching of B-cells and plasma cells. In JANUS, patients treated with atacicept 25 mg or 75 mg experienced stabilization of estimated glomerular filtration rate (eGFR) compared with placebo over 72 weeks. Patients in the atacicept arms also experienced dose …